The Pancreatic Cyst Dilemma
More and more patients are being diagnosed with pancreatic cysts but <1% per year will be malignant.2,3
Balancing the morbidities and mortalities associated with surgical removal of cysts with the high mortality rate of pancreatic cancer can be challenging. Understanding of the risk of malignancy for a cyst can help with decisions as to whether or not surgery is the best option for patients.
Studies have shown that up to 80% of surgeries reveal indolent cysts that didn’t necessarily require surgery.5,6
What if we could help you better predict whether a cyst will remain indolent or become malignant, providing useful information for your surveillance and surgery strategies?
Current Testing Methods
- Today’s standard of care examines risk factors for malignancy based on the patient’s clinical history and the cyst’s image (MRI, CT, EUS), cells (cytology), and fluid proteins (chemistry).
- These approaches provide some information into the properties of a cyst, but do not provide insights into what is occurring in the DNA, where cancer begins.
- Assessing the risk of malignancy using these approaches can be difficult, given their limited insights into cyst biological behavior.
The Solution
PancraGEN® is an integrated molecular pathology test that provides powerful insight into the cumulative DNA mutations present in your patient’s pancreatic cyst. Used in conjunction with chemistry, cytology, and imaging, PancraGEN® provides a tailored, DNA-based risk assessment for cancer in each patient, helping you to improve long-term management strategies.